carnitine has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 9 studies
Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The rising hyperbilirubinemia and transaminitis rapidly and permanently reversed using the amino-acid derivative L-carnitine." | 3.83 | L-Carnitine for Treatment of Pegasparaginase-Induced Hepatotoxicity. ( Alshiekh-Nasany, R; Douer, D, 2016) |
| " An adverse effect of asparaginase includes hepatotoxicity, which can lead to severe liver failure and death." | 2.58 | Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature. ( Baker, WJ; Blackman, A; Boutin, A; Forcello, N; Shimanovsky, A, 2018) |
| "Levocarnitine is a mitochondrial co-factor that can potentially ameliorate the mitochondrial toxicity of asparaginase." | 2.58 | Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature. ( Bleyer, A; Burke, MJ; DuVall, A; Flower, A; Hochberg, J; Madiwale, MV; McNeer, JL; Schulte, RR, 2018) |
| "Levocarnitine has been described as potentially beneficial for the treatment or prevention of PEG-ASP-associated hepatotoxicity." | 1.62 | Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. ( Breese, EH; Burke, MJ; Hinson, A; Huynh, V; McNeer, JL; Mixon, BA; Orgel, E; Pierro, J; Rotz, S; Schulte, R, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Schulte, R | 1 |
| Hinson, A | 1 |
| Huynh, V | 1 |
| Breese, EH | 1 |
| Pierro, J | 1 |
| Rotz, S | 1 |
| Mixon, BA | 1 |
| McNeer, JL | 2 |
| Burke, MJ | 2 |
| Orgel, E | 2 |
| Defina, M | 1 |
| Lazzarotto, D | 1 |
| Guolo, F | 1 |
| Minetto, P | 1 |
| Fracchiolla, NS | 1 |
| Giglio, F | 1 |
| Forghieri, F | 1 |
| Vitale, A | 1 |
| Chiaretti, S | 1 |
| Papayannidis, C | 1 |
| Piccini, M | 1 |
| Mulè, A | 1 |
| Bocchia, M | 1 |
| Leoncin, M | 1 |
| Gurrieri, C | 1 |
| Aprile, L | 1 |
| Lunghi, M | 1 |
| Bonifacio, M | 1 |
| Pasciolla, C | 1 |
| Cerrano, M | 1 |
| Fumagalli, M | 1 |
| Foà, R | 1 |
| Candoni, A | 1 |
| Sea, JL | 1 |
| Chen, T | 1 |
| Paszkiewicz, RL | 1 |
| Krall, AS | 1 |
| Oberley, MJ | 1 |
| Stiles, L | 1 |
| Mittelman, SD | 1 |
| Blackman, A | 1 |
| Boutin, A | 1 |
| Shimanovsky, A | 1 |
| Baker, WJ | 1 |
| Forcello, N | 1 |
| Schulte, RR | 1 |
| Madiwale, MV | 1 |
| Flower, A | 1 |
| Hochberg, J | 1 |
| DuVall, A | 1 |
| Bleyer, A | 1 |
| Liu, Y | 1 |
| Janke, LJ | 1 |
| Li, L | 1 |
| Relling, MV | 1 |
| Alshiekh-Nasany, R | 1 |
| Douer, D | 1 |
| Baker, SK | 1 |
| Lipson, DM | 1 |
| Halonen, P | 1 |
| Salo, MK | 1 |
| Schmiegelow, K | 1 |
| Mäkipernaa, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia[NCT05501899] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-03-03 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for carnitine and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature.
Topics: Adult; Antineoplastic Agents; Asparaginase; Carnitine; Chemical and Drug Induced Liver Injury; Femal | 2018 |
Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carnitine; Chemical and Drug In | 2018 |
7 other studies available for carnitine and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Asparaginase; Carnitine; Chemical and Drug Induced Liver I | 2021 |
Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group.
Topics: Adult; Antineoplastic Agents; Asparaginase; Carnitine; Chemical and Drug Induced Liver Injury; Dieta | 2022 |
Levocarnitine does not impair chemotherapy cytotoxicity against acute lymphoblastic leukemia.
Topics: Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carnitine; Hum | 2020 |
L-carnitine does not ameliorate asparaginase-associated hepatotoxicity in a C57BL6 mouse model.
Topics: Animals; Antineoplastic Agents; Asparaginase; Carnitine; Chemical and Drug Induced Liver Injury; Dis | 2019 |
L-Carnitine for Treatment of Pegasparaginase-Induced Hepatotoxicity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carnit | 2016 |
Vincristine-induced peripheral neuropathy in a neonate with congenital acute lymphoblastic leukemia.
Topics: Acetylcysteine; Antineoplastic Agents, Phytogenic; Carnitine; Drug Therapy, Combination; Free Radica | 2010 |
Investigation of the mechanisms of therapy-related hypoglycaemia in children with acute lymphoblastic leukaemia.
Topics: Adolescent; Alanine; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Carnitine; Child | 2003 |